Remove Containment Remove Licensing Remove Trials
article thumbnail

Trial of Jazz’ cannabis drug in glioblastoma will start next year

pharmaphorum

An investigator-led trial of Jazz Pharma’s cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer – will get underway in the UK next year. The post Trial of Jazz’ cannabis drug in glioblastoma will start next year appeared first on.

Trials 136
article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The response was more powerful than that generated by MenACWY-D – a licensed quadrivalent meningococcal vaccine marketed by GSK. percentage points (96% CI, −0.3

Vaccine 195
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why Proactive AME Studies are Critical to Accelerating Your Approval Journey

Worldwide Clinical Trials

Regardless of the formulation, the entire dose must be administered to each subject, and the dosing containers must be checked for residual radioactivity. The post Why Proactive AME Studies are Critical to Accelerating Your Approval Journey appeared first on Worldwide Clinical Trials.

article thumbnail

Is the microbiome therapy hype up for a reckoning?

Pharmaceutical Technology

Finch Therapeutics’s Phase III PRISM4 trial for recurrent Clostridioides difficile infection (CDI) and MaaT Pharma’s Phase III trial in steroid-resistant acute graft-versus-host disease were both put on hold. While the French MaaT Pharma has submitted further information to the FDA, its trial remains on hold. with placebo.

Bacteria 278
article thumbnail

Mental health apps and services may be doing more harm than good

World of DTC Marketing

DEA agents interviewed former Cerebral employees about clinician licensing issues and allegations that some patients had set up multiple accounts to obtain more drugs, Insider reported , citing sources. A small trial with a positive effect could thus appear unhelpful if its products are combined with less helpful interventions.

Licensing 252
article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891). Hemgenix works by dosing a patient with an engineered adeno-associated virus (AAV), containing the gene responsible for producing a protein called factor IX. Once administered, the body will then be able to produce factor IX and prevent severe bleeds.

article thumbnail

Cantex secures license to develop small molecule-drug for inflammatory lung diseases

pharmaphorum

It is currently the only oral small molecule RAGE inhibitor in human clinical trials. According to Cantex, azeliragon has previously been tested for Alzheimer’s disease and diabetic nephropathy, where the drug demonstrated high levels of safety in phase 3 clinical trials involving more than 2,000 patients.